Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stebvax
- Development stage
- Phase 1
- Lead developer
- Integrated BioTherapeutics
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Parenteral (injection)
01
Overview
STEBVax is a recombinant protein-based vaccine designed to protect against toxic shock syndrome and endotoxic shock caused by Staphylococcus aureus producing the superantigen staphylococcal enterotoxin B (SEB). The vaccine consists of a genetically detoxified recombinant SEB toxoid containing three mutations in the major histocompatibility complex class II binding site. It is formulated with an alum adjuvant (Alhydrogel) and administered parenterally. STEBVax induces functional toxin-neutralizing antibodies that block the activity of SEB, thereby preventing its pathological effects. Clinical studies have shown it to be safe and immunogenic in healthy adults[5][6][1]. The primary developers are Integrated BioTherapeutics and the United States Army Medical Research Institute of Infectious Diseases[2][1].
- Brand names
- STEBVax
- Other names
- Inactivated SEB vaccineInactivated staphylococcal enterotoxin B vaccineSEB vaccineStaphylococcal enterotoxin B vaccine
02
Targets
SEB (Staphylococcal enterotoxin B)
Beyond the preview
Go deeper on stebvax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stebvax.